10D12

10D12 is a murine monoclonal antibody directed against the CD6 co-stimulatory receptor. It serves as a surrogate for clinical-stage anti-CD6 antibodies, such as itolizumab, in preclinical research. 10D12 works by blocking the CD6-ALCAM (Activated Leukocyte Cell Adhesion Molecule) pathway, which is a key regulator of T cell activation, proliferation, and migration. In studies of immune-mediated diseases like lupus nephritis, 10D12 has been shown to reduce renal inflammation, decrease the infiltration of pathogenic T cells and macrophages, and improve clinical markers of kidney function. The antibody was developed and studied through collaborations involving Equillium, the Albert Einstein College of Medicine, and the Cleveland Clinic.

Other names

anti-CD6 mAb 10D12anti-CD-6 mAb 10D12anti-CD 6 mAb 10D12